A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

Trial Profile

A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Bimatoprost (Primary) ; Brimonidine/timolol (Primary)
  • Indications Glaucoma; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 16 Jul 2017 Planned End Date changed from 1 Mar 2018 to 30 Jul 2018.
    • 16 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 30 Jul 2018.
    • 16 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top